Core Viewpoint - MicroPort Medical (00853) reported a revenue of approximately 1.351 billion yuan for HeartPulse Medical (688016.SH) in 2025, marking a year-on-year increase of 11.96%, with a net profit attributable to the parent company of about 563 million yuan, up 12.17% year-on-year, and basic earnings per share of 4.65 yuan [1] Group 1: Financial Performance - The total revenue for the reporting period was approximately 1.351 billion yuan, reflecting a year-on-year growth of 11.96% [1] - The net profit attributable to the parent company was around 563 million yuan, showing a year-on-year increase of 12.17% [1] - Basic earnings per share were reported at 4.65 yuan [1] Group 2: Product Development and Market Strategy - The company has accelerated the promotion of new products and replacement of old products through strategies such as market penetration, customized treatment solutions, and product upgrades, leading to a steady increase in market share [1] - The company launched multiple innovative products in the domestic market, including the Cratos branched aortic stent graft system and other medical devices, with a total of 23 products receiving NMPA registration and 11 products obtaining registration in 28 overseas markets [2] - The company has a rich pipeline of products under development, with several products like the Aegis II abdominal aortic stent graft system and Hector thoracic multi-branch stent graft system progressing through various stages of clinical trials and regulatory submissions [3] Group 3: International Sales and Market Expansion - Overseas sales revenue exceeded 250 million yuan, representing a growth of over 55%, contributing to more than 18% of the company's total revenue [1] - The company is actively pursuing collaborations with leading regional clients globally and advancing the market access and promotion of aortic and peripheral interventional products in Europe, Latin America, and Asia-Pacific [1] - The company’s products are now sold in 49 countries and regions, including China [1]
微创医疗:心脉医疗 2025年归母净利约5.63亿元,同比增长12.17%